Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 15.8% in November

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large increase in short interest in November. As of November 30th, there was short interest totalling 11,000 shares, an increase of 15.8% from the November 15th total of 9,500 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily volume of 25,400 shares, the days-to-cover ratio is presently 0.4 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Aprea Therapeutics in a report on Monday, November 18th.

Aprea Therapeutics Stock Down 9.2 %

NASDAQ APRE traded down $0.32 on Friday, reaching $3.20. The company had a trading volume of 25,108 shares, compared to its average volume of 20,368. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $8.85. The firm’s 50 day moving average price is $3.41 and its 200 day moving average price is $3.60. The stock has a market capitalization of $17.36 million, a PE ratio of -1.13 and a beta of 0.88.

Aprea Therapeutics (NASDAQ:APRE) last released its earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. On average, research analysts expect that Aprea Therapeutics will post -2.55 EPS for the current year.

Insider Buying and Selling at Aprea Therapeutics

In other Aprea Therapeutics news, Director Bernd R. Seizinger acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The shares were bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the acquisition, the director now owns 44,730 shares in the company, valued at $119,876.40. This represents a 28.79 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Marc Duey acquired 30,000 shares of Aprea Therapeutics stock in a transaction dated Wednesday, October 16th. The stock was bought at an average price of $4.39 per share, with a total value of $131,700.00. Following the completion of the purchase, the director now directly owns 240,113 shares in the company, valued at $1,054,096.07. This represents a 14.28 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 42,290 shares of company stock worth $165,096. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up approximately 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.